Scarica l'app Stockscreener
9.915
1.02%
0.125
Precedente Chiudi:
$9.79
Aprire:
$9.81
Volume 24 ore:
59,047
Relative Volume:
0.06
Capitalizzazione di mercato:
$581.83M
Reddito:
$106.47M
Utile/perdita netta:
$82.89M
Rapporto P/E:
6.6383
EPS:
1.4936
Flusso di cassa netto:
$-2.43M
1 W Prestazione:
+3.13%
1M Prestazione:
-0.90%
6M Prestazione:
-16.04%
1 anno Prestazione:
+42.10%
Intervallo 1D:
$9.81
$9.95
Intervallo di 1 settimana:
$9.35
$9.95
Portata 52W:
$6.7701
$13.16
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Nome
Zevra Therapeutics Inc
Settore
Industria
Telefono
(888) 958-1253
Indirizzo
101 FEDERAL STREET, BOSTON
Compare ZVRA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
9.91 | 574.79M | 106.47M | 82.89M | -2.43M | 1.4936 |
VRTX
Vertex Pharmaceuticals Inc
|
441.25 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.88 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
845.84 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
334.76 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.79 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Iniziato | BTIG Research | Buy |
| 2025-07-02 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-08 | Ripresa | Cantor Fitzgerald | Overweight |
| 2024-10-07 | Iniziato | Guggenheim | Buy |
| 2024-09-24 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-09-24 | Reiterato | Maxim Group | Buy |
| 2024-04-02 | Reiterato | Maxim Group | Buy |
| 2024-03-12 | Iniziato | William Blair | Outperform |
| 2023-03-17 | Iniziato | Maxim Group | Buy |
Mostra tutto
Zevra Therapeutics Inc Borsa (ZVRA) Ultime notizie
Short Squeeze: Will Zevra Therapeutics Inc benefit from geopolitical trendsMarket Performance Summary & Free Verified High Yield Trade Plans - baoquankhu1.vn
Moving Averages: Can Zevra Therapeutics Inc maintain sales growth2026 Support & Resistance & AI Enhanced Execution Alerts - baoquankhu1.vn
ZVRA SEC FilingsZevra Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Published on: 2026-04-10 05:39:10 - baoquankhu1.vn
ZVRA Stock Price, Quote & Chart | ZEVRA THERAPEUTICS INC (NASDAQ:ZVRA) - ChartMill
Returns Recap: Should I add Zevra Therapeutics Inc stock to my portfolioMarket Performance Report & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Stratos Wealth Partners LTD. Boosts Stake in Zevra Therapeutics, Inc. $ZVRA - MarketBeat
Zevra Therapeutics (NASDAQ: ZVRA) posts $106.5M 2025 revenue; proxy items - Stock Titan
ZVRA Technical Analysis | Trend, Signals & Chart Patterns | ZEVRA THERAPEUTICS INC (NASDAQ:ZVRA) - ChartMill
Zevra shares jump after selling SDX portfolio for $50M - MSN
(ZVRA) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
JPMorgan Chase & Co. Has $4.18 Million Stock Holdings in Zevra Therapeutics, Inc. $ZVRA - marketbeat.com
Zevra Therapeutics Inc (1GDA.HM) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
ZVRA PE Ratio & Valuation, Is ZVRA Overvalued - Intellectia AI
ZVRA Financials: Revenue Breakdown, Margins & Competitor Comparison - intellectia.ai
Hennion & Walsh Asset Management Inc. Invests $1.25 Million in Zevra Therapeutics, Inc. $ZVRA - MarketBeat
Zevra Therapeutics Earnings Call Signals Profitable Turn - The Globe and Mail
Zevra Therapeutics Inc (1GDA.HM) interactive stock chart - Yahoo Finance UK
Sentiment Recap: Will Zevra Therapeutics Inc benefit from geopolitical trendsTrade Entry Report & Community Supported Trade Ideas - baoquankhu1.vn
Nio, Zevra Therapeutics, Vertex Pharmaceuticals and other big stocks moving higher on Tuesday - MSN
Dividend Watch: Is Zevra Therapeutics Inc forming bullish engulfing patternsWeekly Risk Summary & Real-Time Buy Zone Alerts - baoquankhu1.vn
Zevra Therapeutics Inc (1GDA.HM) stock historical prices and data - Yahoo Finance UK
Vanguard realignment: affiliates to report ZVRA holdings separately (ZVRA) - stocktitan.net
John B Bode At Zevra Therapeutics Executes Options Exercise, Realizing $326K - Benzinga
How (ZVRA) Movements Inform Risk Allocation Models - Stock Traders Daily
Is GeneDx (WGS) Using Sponsored NPC Testing to Quietly Strengthen Its Data Advantage? - Yahoo Finance
Hypersomnia Pipeline Advances with 3+ Companies Developing Innovative Therapies and Expanding Clinical Research | DelveInsight - Barchart
Citizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PT - MSN
Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer under Nasdaq Listing Rule 5635(4) - MarketScreener
Zevra Ties NPC Testing Push To Valuation Gap And New CFO - Yahoo Finance
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Published on: 2026-03-21 14:23:45 - baoquankhu1.vn
Assessing Zevra Therapeutics (ZVRA) Valuation After Recent Share Price Moves And Rare Disease Milestone - Sahm
Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
GeneDx (WGS), Zevra Therapeutics (ZVRA) partner to launch sponsored genetic testing program for NPC - MSN
GeneDx (WGS), Zevra Therapeutics (ZVRA) Partner to Launch Sponsored Genetic Testing Program for NPC - Yahoo Finance
New Zevra finance chief gets a 300,000-share stock option - Stock Titan
Zevra Therapeutics announced that, in accordance with Nasdaq Listing Rule 5635(C)(4), it has granted an inducement equity award to the company's new Chief Financial Officer. - Bitget
CFO at Zevra (NASDAQ: ZVRA) receives 300,000-share option grant - Stock Titan
Zevra Therapeutics (ZVRA) CFO Justin Renz files insider ownership report - Stock Titan
Zevra Therapeutics appoints Justin Renz as CFO - MSN
XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements - GlobeNewswire Inc.
BTIG initiates Zevra Therapeutics stock with buy on Miplyffa outlook - Investing.com Nigeria
R. LaDuane Clifton (ZVRA) files Form 144 showing 11,000‑ and 3,000‑share sales - Stock Titan
Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million and Settles Delaware Lawsuit 1 - Minichart
Zevra Therapeutics (NASDAQ:ZVRA) Shares Gap UpStill a Buy? - MarketBeat
Zevra Therapeutics Agrees to Sell SDX Portfolio to Commave Therapeutics for $50 Million - marketscreener.com
Zevra Shares Jump After Selling SDX Portfolio For $50M - Benzinga
Zevra Therapeutics, Inc.Common Stock (NQ: ZVRA - markets.chroniclejournal.com
BTIG initiates Zevra Therapeutics stock with buy on Miplyffa outlook By Investing.com - Investing.com Australia
Zevra Therapeutics (NASDAQ:ZVRA) Now Covered by BTIG Research - MarketBeat
Zevra Therapeutics Inc Azioni (ZVRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.76%
0.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):